Cargando…
The cost-effectiveness of neoadjuvant chemotherapy in women with locally advanced breast cancer: Adriamycin and cyclophosphamide in comparison with paclitaxel and gemcitabine
BACKGROUND: A decision analysis model was developed to assess the cost-effectiveness of adriamycin and cyclophosphamide (AC) in comparison with paclitaxel and gemcitabine (PG) in women with advanced breast cancer in Iran. MATERIALS AND METHODS: This is a cost-effectiveness analysis performed as a cr...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6040151/ https://www.ncbi.nlm.nih.gov/pubmed/30057641 http://dx.doi.org/10.4103/jrms.JRMS_644_17 |
_version_ | 1783338806096691200 |
---|---|
author | Javan-Noughabi, Javad Rezapour, Aziz Kassani, Aziz Hatam, Nahid Ahmadloo, Niloofar |
author_facet | Javan-Noughabi, Javad Rezapour, Aziz Kassani, Aziz Hatam, Nahid Ahmadloo, Niloofar |
author_sort | Javan-Noughabi, Javad |
collection | PubMed |
description | BACKGROUND: A decision analysis model was developed to assess the cost-effectiveness of adriamycin and cyclophosphamide (AC) in comparison with paclitaxel and gemcitabine (PG) in women with advanced breast cancer in Iran. MATERIALS AND METHODS: This is a cost-effectiveness analysis performed as a cross-sectional study in Namazi Hospital in Shiraz, Iran. Patients were divided into two groups by random numbers, 32 women in the AC group and 32 women in the PG group. The costs were measured using the societal perspective and effectiveness of 2 regimens were assessed using tumor response. By a decision tree, the incremental cost-effectiveness ratio was calculated. In addition, the robustness of results was examined by sensitivity analysis. RESULTS: The estimated total cost of AC and PG per patient was 1565.23 ± 765.31 and 2099.08 ± 926.99, respectively. Response to treatment in AC and PG arm were 84% versus 75% respectively. The incremental cost-effectiveness ratio results showed AC is a dominate alternative. CONCLUSION: Overall, AC was a simple dominate strategy. In other words, AC was estimated to have a lower cost and greater effectiveness than PG. |
format | Online Article Text |
id | pubmed-6040151 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-60401512018-07-27 The cost-effectiveness of neoadjuvant chemotherapy in women with locally advanced breast cancer: Adriamycin and cyclophosphamide in comparison with paclitaxel and gemcitabine Javan-Noughabi, Javad Rezapour, Aziz Kassani, Aziz Hatam, Nahid Ahmadloo, Niloofar J Res Med Sci Original Article BACKGROUND: A decision analysis model was developed to assess the cost-effectiveness of adriamycin and cyclophosphamide (AC) in comparison with paclitaxel and gemcitabine (PG) in women with advanced breast cancer in Iran. MATERIALS AND METHODS: This is a cost-effectiveness analysis performed as a cross-sectional study in Namazi Hospital in Shiraz, Iran. Patients were divided into two groups by random numbers, 32 women in the AC group and 32 women in the PG group. The costs were measured using the societal perspective and effectiveness of 2 regimens were assessed using tumor response. By a decision tree, the incremental cost-effectiveness ratio was calculated. In addition, the robustness of results was examined by sensitivity analysis. RESULTS: The estimated total cost of AC and PG per patient was 1565.23 ± 765.31 and 2099.08 ± 926.99, respectively. Response to treatment in AC and PG arm were 84% versus 75% respectively. The incremental cost-effectiveness ratio results showed AC is a dominate alternative. CONCLUSION: Overall, AC was a simple dominate strategy. In other words, AC was estimated to have a lower cost and greater effectiveness than PG. Medknow Publications & Media Pvt Ltd 2018-06-06 /pmc/articles/PMC6040151/ /pubmed/30057641 http://dx.doi.org/10.4103/jrms.JRMS_644_17 Text en Copyright: © 2018 Journal of Research in Medical Sciences http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Original Article Javan-Noughabi, Javad Rezapour, Aziz Kassani, Aziz Hatam, Nahid Ahmadloo, Niloofar The cost-effectiveness of neoadjuvant chemotherapy in women with locally advanced breast cancer: Adriamycin and cyclophosphamide in comparison with paclitaxel and gemcitabine |
title | The cost-effectiveness of neoadjuvant chemotherapy in women with locally advanced breast cancer: Adriamycin and cyclophosphamide in comparison with paclitaxel and gemcitabine |
title_full | The cost-effectiveness of neoadjuvant chemotherapy in women with locally advanced breast cancer: Adriamycin and cyclophosphamide in comparison with paclitaxel and gemcitabine |
title_fullStr | The cost-effectiveness of neoadjuvant chemotherapy in women with locally advanced breast cancer: Adriamycin and cyclophosphamide in comparison with paclitaxel and gemcitabine |
title_full_unstemmed | The cost-effectiveness of neoadjuvant chemotherapy in women with locally advanced breast cancer: Adriamycin and cyclophosphamide in comparison with paclitaxel and gemcitabine |
title_short | The cost-effectiveness of neoadjuvant chemotherapy in women with locally advanced breast cancer: Adriamycin and cyclophosphamide in comparison with paclitaxel and gemcitabine |
title_sort | cost-effectiveness of neoadjuvant chemotherapy in women with locally advanced breast cancer: adriamycin and cyclophosphamide in comparison with paclitaxel and gemcitabine |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6040151/ https://www.ncbi.nlm.nih.gov/pubmed/30057641 http://dx.doi.org/10.4103/jrms.JRMS_644_17 |
work_keys_str_mv | AT javannoughabijavad thecosteffectivenessofneoadjuvantchemotherapyinwomenwithlocallyadvancedbreastcanceradriamycinandcyclophosphamideincomparisonwithpaclitaxelandgemcitabine AT rezapouraziz thecosteffectivenessofneoadjuvantchemotherapyinwomenwithlocallyadvancedbreastcanceradriamycinandcyclophosphamideincomparisonwithpaclitaxelandgemcitabine AT kassaniaziz thecosteffectivenessofneoadjuvantchemotherapyinwomenwithlocallyadvancedbreastcanceradriamycinandcyclophosphamideincomparisonwithpaclitaxelandgemcitabine AT hatamnahid thecosteffectivenessofneoadjuvantchemotherapyinwomenwithlocallyadvancedbreastcanceradriamycinandcyclophosphamideincomparisonwithpaclitaxelandgemcitabine AT ahmadlooniloofar thecosteffectivenessofneoadjuvantchemotherapyinwomenwithlocallyadvancedbreastcanceradriamycinandcyclophosphamideincomparisonwithpaclitaxelandgemcitabine AT javannoughabijavad costeffectivenessofneoadjuvantchemotherapyinwomenwithlocallyadvancedbreastcanceradriamycinandcyclophosphamideincomparisonwithpaclitaxelandgemcitabine AT rezapouraziz costeffectivenessofneoadjuvantchemotherapyinwomenwithlocallyadvancedbreastcanceradriamycinandcyclophosphamideincomparisonwithpaclitaxelandgemcitabine AT kassaniaziz costeffectivenessofneoadjuvantchemotherapyinwomenwithlocallyadvancedbreastcanceradriamycinandcyclophosphamideincomparisonwithpaclitaxelandgemcitabine AT hatamnahid costeffectivenessofneoadjuvantchemotherapyinwomenwithlocallyadvancedbreastcanceradriamycinandcyclophosphamideincomparisonwithpaclitaxelandgemcitabine AT ahmadlooniloofar costeffectivenessofneoadjuvantchemotherapyinwomenwithlocallyadvancedbreastcanceradriamycinandcyclophosphamideincomparisonwithpaclitaxelandgemcitabine |